SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-184045
Filing Date
2020-06-30
Accepted
2020-06-30 16:17:56
Documents
15
Period of Report
2020-06-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d949115d8k.htm   iXBRL 8-K 34928
2 EX-99.1 d949115dex991.htm EX-99.1 20135
6 GRAPHIC g949115g20m80.jpg GRAPHIC 2371
7 GRAPHIC g949115g38u73.jpg GRAPHIC 3768
  Complete submission text file 0001193125-20-184045.txt   199788

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gthx-20200629.xsd EX-101.SCH 3087
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gthx-20200629_lab.xml EX-101.LAB 18907
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gthx-20200629_pre.xml EX-101.PRE 11874
8 EXTRACTED XBRL INSTANCE DOCUMENT d949115d8k_htm.xml XML 3478
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 201002527
SIC: 2834 Pharmaceutical Preparations